3 July 2025 - Biocon Biologics today announced that the European Commission has granted marketing authorisation in the European Union for Vevzuo and Evfraxy biosimilars of denosumab.

Vevzuo is authorised for the prevention of bone complications in adults with advanced cancer involving bone and the treatment of adults and skeletally mature adolescents with giant cell tumour of bone.

Read Biocon press release